ArticleBMC psychiatry2012
Infant and childhood neurodevelopmental outcomes following prenatal exposure to selective serotonin reuptake inhibitors: overview and design of a Finnish Register-Based Study (FinESSI).
Article in BMC psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.
- A Systematic Review of Algorithms for Identifying Pediatric Neurodevelopmental Outcomes.Pharmacoepidemiology and drug safety · 2025Pooled it
- Maternal SSRI use during pregnancy and offspring depression or anxiety disorders: A review of the literature and description of a study protocol for a register-based cohort study.Reproductive toxicology (Elmsford, N.Y.) · 2023Review
- Gene×environment interactions in autism spectrum disorders.Current topics in developmental biology · 2023Review
- Article
- Interactions between maternal fluoxetine exposure, the maternal gut microbiome and fetal neurodevelopment in mice.Behavioural brain research · 2021Article
- The MATEX cohort - a Finnish population register birth cohort to study health effects of prenatal exposures.BMC public health · 2017Article
- New Insights into How Serotonin Selective Reuptake Inhibitors Shape the Developing Brain.Birth defects research · 2017Review
- Gestational Exposure to Selective Serotonin Reuptake Inhibitors and Offspring Psychiatric Disorders: A National Register-Based Study.Journal of the American Academy of Child and Adolescent Psychiatry · 2016Article
- Monoamine-sensitive developmental periods impacting adult emotional and cognitive behaviors.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2015Review
- Rate of Chiari I malformation in children of mothers with depression with and without prenatal SSRI exposure.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2014Article
- Specialized service use for psychiatric and neurodevelopmental disorders by age 14 in Finland.Psychiatric services (Washington, D.C.) · 2014Article
- The effects of antenatal depression and antidepressant treatment on placental gene expression.Frontiers in cellular neuroscience · 2014Article
- Selective serotonin reuptake inhibitors and pregnancy: A review of maternal, fetal and neonatal risks and benefits.Obstetric medicine · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundExperimental animal studies and one population-based study have suggested an increased risk for adverse neurodevelopmental outcome after prenatal exposure to SSRIs. We describe the methods and design of a population-based study examining the association between prenatal SSRI exposure and neurodevelopment until age 14. METHODS AND
designThis is a cohort study of national registers in Finland: the Medical Birth Register, the Register of Congenital Malformations, the Hospital Discharge Register including inpatient and outpatient data, the Drug Reimbursement Register, and the Population Register. The total study population includes 845,345 women and their live-born, singleton offspring aged 14 or younger and born during Jan 1st 1996-Dec 31st 2010. We will compare the prevalence of psychiatric and neurodevelopmental outcomes in offspring exposed prenatally to SSRIs to offspring exposed to prenatal depression and unexposed to SSRIs. Associations between exposure and outcome are assessed by statistical methods including specific modeling to account for correlated outcomes within families and differences in duration of follow-up between the exposure groups. Descriptive results. Of all pregnant women with pregnancy ending in delivery (n=859,359), 1.9% used SSRIs. The prevalence of diagnosed depression and depression-related psychiatric disorders within one year before or during pregnancy was 1.7%. The cumulative incidence of registered psychiatric or neurodevelopmental disorders was 6.9% in 2010 among all offspring born during the study period (age range 0-14 years). DISCUSSION: The study has the potential for significant public health importance in providing information on prenatal exposure to SSRIs and long-term neurodevelopment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.